How clarithromycin affects sleepiness in certain neurological disorders
Antibiotic-mediated improvements in vigilance: mechanisms of action of clarithromycin in hypersomnia syndromes
This study is looking at how the antibiotic clarithromycin might help people with excessive daytime sleepiness, especially those with conditions like idiopathic hypersomnia and narcolepsy type 2, by exploring how it affects brain activity and other factors in the body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10685574 on NIH RePORTER |
What this research studies
This research investigates the effects of the antibiotic clarithromycin on excessive daytime sleepiness, a common symptom in neurological disorders like idiopathic hypersomnia and narcolepsy type 2. The study will involve a randomized, placebo-controlled trial to determine how clarithromycin reduces sleepiness and to identify the biological mechanisms behind this effect. Patients will be monitored for changes in brain activity, neurotransmitter levels, and gut microbiome composition to understand how the medication works. The goal is to provide insights that could lead to better treatments for those suffering from these debilitating conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic hypersomnia or narcolepsy type 2 who experience excessive daytime sleepiness.
Not a fit: Patients with sleepiness not related to neurological disorders or those who do not meet the specific diagnostic criteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients suffering from excessive daytime sleepiness associated with neurological disorders.
How similar studies have performed: Previous studies have shown that clarithromycin can effectively reduce sleepiness in similar conditions, suggesting a promising avenue for further investigation.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Trotti, Lynn Marie — Emory University
- Study coordinator: Trotti, Lynn Marie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.